Zacharias Wijfjes

Zacharias Wijfjes

Auto-generated profile, based on publicly available information

Zacharias Wijfjes

Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2023 in Molecular Pharmaceutics
Verified
Journal Article
Open access
ZWZacharias Wijfjes
Zacharias Wijfjes
FDFloris J. van Dalen
Floris J. van Dalen
CGCamille M. Le Gall
Camille M. Le Gall
MVMartijn Verdoes
Martijn Verdoes
Antigen-presenting cells (APCs) orchestrate immune responses and are therefore of interest for the targeted delivery of therapeutic vaccines. Dendritic cells (DCs) are professional APCs that excel in presentation of exogenous antigens toward CD4+ T helper cells, as well as cytotoxic CD8+ T cells. DCs are highly heterogeneous and can be divided into subpopulations that differ in abundance, function, and phenotype, such as differential expression of endocytic receptor molecules. It is firmly established that targeting antigens to DC receptors enhances the efficacy of therapeutic vaccines. While most studies emphasize the importance of targeting a specific DC subset, we argue that the differential intracellular routing downstream of the targeted receptors within the DC subset should also be considered. Here, we review the mouse and human receptors studied as target for therapeutic vaccines, focusing on antibody and ligand conjugates and how their targeting affects antigen presentation. We aim to delineate how targeting distinct receptors affects antigen presentation and vaccine efficacy, which will guide target selection for future therapeutic vaccine development.

15 April 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CGCamille Le Gall
Camille Le Gall
ACAnna Cammarata
Anna Cammarata
LHLukas de Haas
Lukas de Haas
Iván Ramos-TomilleroIván Ramos-Tomillero
Iván Ramos-Tomillero
JCJorge Cuenca-Escalona
Jorge Cuenca-Escalona
MVMartijn Verdoes
Martijn Verdoes
Background: Type 1 conventional dendritic cells (cDC1s) are characterized by their ability to induce potent CD8+ T cell responses. In efforts to generate novel vaccination strategies, notably against cancer, human cDC1s emerge as an ideal target to deliver antigens. cDC1s uniquely express XCR1, a seven transmembrane G protein-coupled receptor. Due to its restricted expression and endocytic nature, XCR1 represents an attractive receptor to mediate antigen-delivery to human cDC1s. Methods: To explore tumor antigen delivery to human cDC1s, we used an engineered version of XCR1-binding lymphotactin (XCL1), XCL1(CC3). Site-specific sortase-mediated transpeptidation was performed to conjugate XCL1(CC3) to an analog of the HLA-A*02:01 epitope of the cancer testis antigen New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1). While poor epitope solubility prevented isolation of stable XCL1-antigen conjugates, incorporation of a single polyethylene glycol (PEG) chain upstream of the epitope-containing peptide enabled generation of soluble XCL1(CC3)-antigen fusion constructs. Binding and chemotactic characteristics of the XCL1-antigen conjugate, as well as its ability to induce antigen-specific CD8+ T cell activation by cDC1s, was assessed. Results: PEGylated XCL1(CC3)-antigen conjugates retained binding to XCR1, and induced cDC1 chemoattraction in vitro. The model epitope was efficiently cross-presented by human cDC1s to activate NY-ESO-1-specific CD8+ T cells. Importantly, vaccine activity was increased by targeting XCR1 at the surface of cDC1s. Conclusion: Our results present a novel strategy for the generation of targeted vaccines fused to insoluble antigens. Moreover, our data emphasize the potential of targeting XCR1 at the surface of primary human cDC1s to induce potent CD8+ T cell responses.

9 April 2025 in Nature Biomedical Engineering
Verified
Journal Article
Open access
PDF file
AHAngela F. el Hebieshy
Angela F. el Hebieshy
ZWZacharias Wijfjes
Zacharias Wijfjes
CGCamille M. Le Gall
Camille M. Le Gall
JMJim Middelburg
Jim Middelburg
KRKim Elisa De Roode
Kim Elisa De Roode
FSFerenc A Scheeren
Ferenc A Scheeren
Antibody conjugates are the foundation of a wide range of diagnostic and therapeutic applications. Although many antibody-conjugation techniques are robust and efficient, obtaining homogeneous multimeric conjugation products remains challenging. Here we report a modular and versatile technique for the site-directed multivalent conjugation of antibodies via the small-protein ubiquitin. Specifically, multiple ubiquitin fusions with antibodies, antibody fragments, nanobodies, peptides or small molecules such as fluorescent dyes can be conjugated to antibodies and nanobodies within 30 min. The technique, which we named ‘ubi-tagging’, allowed us to efficiently generate a bispecific T-cell engager as well as nanobodies conjugated to dendritic-cell-targeted antigens that led to potent T-cell responses. Using both recombinant ubi-tagged proteins and synthetic ubiquitin derivatives allows for the iterative, site-directed and multivalent conjugation of antibodies and nanobodies to a plethora of molecular moieties.

5 May 2025 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
ZWZacharias Wijfjes
Zacharias Wijfjes
ITIván Ramos Tomillero
Iván Ramos Tomillero
CGCamille M. Le Gall
Camille M. Le Gall
EDEric A. W. van Dinther
Eric A. W. van Dinther
FTFrederique Turlings
Frederique Turlings
MVMartijn Verdoes
Martijn Verdoes
The aim of therapeutic cancer vaccines is to induce tumor-specific cellular immune responses. This requires tumor antigens to be efficiently processed and presented by antigen-presenting cells, in particular dendritic cells (DCs). In addition, DCs require maturation to upregulate the surface expression and secretion of T cell costimulatory molecules, which is achieved by co-administration of adjuvants in vaccines. Peptide-based antigen vaccination is an attractive strategy due to the established biocompatibility of peptides as well as the dosing control. To enhance the efficacy of peptide-based vaccines, antigens can be targeted to DCs. Antigen–adjuvant conjugates are known to enhance T cell activation by ensuring DC maturation upon antigen delivery. In this study, we aim to combine these two approaches in a single molecule, and present a DC-targeted antibody fragment–antigen–adjuvant (AAA)-conjugate. We generate the AAA-conjugate through a combination of site-specific sortase-mediated chemoenzymatic ligation and click chemistry. Ex vivo T cell activation assays show enhanced efficacy of the AAA-conjugate compared to non-adjuvanted control conjugates. The in vivo performance of the AAA-conjugate was suboptimal, which we hypothesize to be a consequence of the hydrophobic character of the conjugate. In vivo efficacy was rescued by co-administration of antibody fragment–antigen conjugates and antibody fragment-adjuvant conjugates, in which the antigen and adjuvant were separatedly delivered using two different DC-targeting molecules. In conclusion, this study provides a proof-of-concept for effective in vivo antigen-specific T cell activation by targeted delivery of both antigen and adjuvant to DCs in a single or separate molecule using site-specific protein engineering.

Verified
Journal Article
Open access
PDF file
MEMarit J. van Elsas
Marit J. van Elsas
JSJohan M. S. van der Schoot
Johan M. S. van der Schoot
ABAlexander Bartels
Alexander Bartels
KSKas Steuten
Kas Steuten
DDDuco van Dalen
Duco van Dalen
FSFerenc A Scheeren
Ferenc A Scheeren
Regulatory T cells (Tregs) are major drivers behind immunosuppressive mechanisms and present a major hurdle for cancer therapy. Tregs are characterized by a high expression of CD25, which is a potentially valuable target for Treg depletion to alleviate immune suppression. The preclinical anti-CD25 (αCD25) antibody, clone PC-61, has met with modest anti-tumor activity due to its capacity to clear Tregs from the circulation and lymph nodes, but not those that reside in the tumor. The optimization of the Fc domain of this antibody clone has been shown to enhance the intratumoral Treg depletion capacity. Here, we generated a stable cell line that produced optimized recombinant Treg-depleting antibodies. A genome engineering strategy in which CRISPR-Cas9 was combined with homology-directed repair (CRISPR-HDR) was utilized to optimize the Fc domain of the hybridoma PC-61 for effector functions by switching it from its original rat IgG1 to a mouse IgG2a isotype. In a syngeneic tumor mouse model, the resulting αCD25-m2a (mouse IgG2a isotype) antibody mediated the effective depletion of tumor-resident Tregs, leading to a high effector T cell (Teff) to Treg ratio. Moreover, a combination of αCD25-m2a and an αPD-L1 treatment augmented tumor eradication in mice, demonstrating the potential for αCD25 as a cancer immunotherapy.

8 December 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
ARAndrea Rodgers-Furones
Andrea Rodgers-Furones
TBThijs Brands
Thijs Brands
GGGuusje van Gameren
Guusje van Gameren
MFMirane Florencio-Zabaleta
Mirane Florencio-Zabaleta
MBMayukha Bathini
Mayukha Bathini
LCLaia Querol Cano
Laia Querol Cano
To initiate T cell–mediated immunity, dendritic cells (DCs) present antigens to T cells through the establishment of an immune synapse (IS). While events behind IS formation in T cells are well understood, the organization of IS components at the DC membrane remains ill-defined. Galectins modulate immune responses via glycan-(in)dependent interactions but the molecular mechanisms underlying their function in DC–mediated T cell activation, are poorly described. Here, we demonstrate that intracellular galectin-9 (gal9) in DCs is required for CD4 + T cell activation through its interaction with the HLA-DR alpha- and beta- cytoplasmic domains, as supported by coimmunoprecipitation, mass spectrometry, and NMR analyses. Live-cell imaging revealed gal9-depleted DCs fail to establish stable ISs with T cells, reducing T cell activation and proliferation. Notably, HLA-DR membrane lateral mobility and recruitment to the IS was diminished in DCs lacking gal9. Conditional gal9 knockout in DCs led to enhanced tumor growth in vivo, underscoring a role for gal9 in T cell–dependent antitumor immunity. Collectively, this study reports gal9-mediated HLA-DR organization at the DC synapse, uncovering a mechanism through which intracellular galectins coordinate immune receptor positioning to enhance CD4 + T cell activation.